Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenomics Aims to Raise $300M Through Common Stock, Senior Notes Offerings

NEW YORK – NeoGenomics announced Thursday the pricing of its proposed offerings of shares of common stock and convertible senior notes.

The company is offering 4.4 million shares of its common stock at $28.50 per share, with expected gross proceeds of $125.4 million, and $175 million of its 1.25 percent convertible senior notes due in 2025. The senior notes will mature on May 1, 2025. 

NeoGenomics also granted the underwriters of the offerings a 30-day option to buy an additional 666,000 shares of common stock at the public offering price and $26.25 million of senior notes.

For the common stock offering, the underwriters are also offering approximately 1,065,000 shares of common stock borrowed from third parties. They will use the resulting short position to facilitate hedging transactions by some of the purchasers of the senior notes, the company said.

Fort Myers, Florida-based NeoGenomics said it will use the proceeds for general corporate purposes and to repay borrowings under its term loan facility. It may also use some of the proceeds for acquisitions or investments. 

Morgan Stanley, BofA Securities, and SVB Leerink represented the underwriters and book-running managers for the offerings, which are expected to close on May 4. William Blair, Craig-Hallum Capital Group, Needham & Company, and Raymond James were co-managers for the offerings.

In morning trading on the Nasdaq, NeoGenomics' shares were down 10 percent to $27.98.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.